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27599, USANeuronal ceroid lipofuscinoses (NCLs; Batten disease) are
neurodegenerative lysosomal storage diseases predominantly
affecting children. Single administration of brain-directed len-
tiviral or recombinant single-stranded adeno-associated virus 9
(ssAAV9) vectors expressing ovine CLN5 into six pre-clinically
affected sheep with a naturally occurring CLN5NCL resulted in
long-term disease attenuation. Treatment efficacy was demon-
strated by non-invasive longitudinal in vivo monitoring devel-
oped to align with assessments used in human medicine. The
treated sheep retained neurological and cognitive function,
and one ssAAV9-treated animal has been retained and is now
57 months old, almost triple the lifespan of untreated CLN5-
affected sheep. The onset of visual deficits was much delayed.
Computed tomography and MRI showed that brain structures
and volumes remained stable. Because gene therapy in humans
is more likely to begin after clinical diagnosis, self-complemen-
tary AAV9-CLN5 was injected into the brain ventricles of four
7-month-old affected sheep already showing early clinical signs
in a second trial. This also halted disease progression beyond
their natural lifespan. These findings demonstrate the efficacy
of CLN5 gene therapy, using three different vector platforms,
in a large animal model and, thus, the prognosis for human
translation.Received 21 January 2018; accepted 12 July 2018;
https://doi.org/10.1016/j.ymthe.2018.07.015.
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Batten disease (neuronal ceroid lipofuscinoses [NCLs]) are fatal in-
herited lysosomal storage diseases affecting the CNS and are caused
by mutations in any of 13 different genes, designated CLN1–CLN8
and CLN10–CLN14 (http://www.ucl.ac.uk/ncl). Despite their genetic
diversity, NCLs are defined by similar pathological and clinical fea-
tures that include progressive neuronal loss, retinal degeneration, sei-
zures, and psychomotor decline, culminating in premature death.1
Apart from a recently approved enzyme replacement therapy
for the CLN2 disease (cerliponase alfa, BioMarin Pharmaceutical),
there are no effective treatments, although several gene and
enzyme replacement therapy trials are underway (NCT01161576,2366 Molecular Therapy Vol. 26 No 10 October 2018 ª 2018 The AmeNCT01414985, NCT02485899, and NCT02725580; https://
clinicaltrials.gov) following studies in animal models.2–6
Disease-relevant animal models are invaluable for the development
and validation of therapies. However, encouraging preliminary data
from gene therapy studies in murine forms2,3,7,8 need careful consid-
eration before proceeding to translation in human medicine because
there are serious caveats with studies in mice. The lissencephalic
mouse brain lacks major neuroanatomical structures prominent in
the human brain and is very much smaller, 0.4 g versus 1.4 kg, and
the neuropathology in many NCL mouse models varies from that
seen in the analogous human diseases.9 Studies using larger animal
models with a CNS, physiology, and genomic organization compara-
ble with humans should prove more informative.10
Sheep with naturally occurring disease provide ideal models, being
similarly sized as humans, weighing 3.5–4.5 kg at birth and growing
to 80- to 110-kg adults. The gyrencephalic ovine brain is similar in
physical organization to the human brain and in size to non-human
primate brains, providing a good approximation for dose requirements,
vector distribution, and the utility of gene therapy strategies in pediatric
neurodegenerative disorders. The executive function and cognitive ca-
pabilities of sheep are now being recognized,11–13 and their longevity
(9–12 years) allows monitoring of the clinical effectiveness and the
longer-term consequences of gene therapies over a time frame relevant
to disease. Because such trials take several years, and the downstream
consequences of successful treatments will require monitoring, there
is a pressing need to harvest translational data in vivo and allow success-
ful trials to continue without prematurely sacrificing animals for post
mortem neuropathological evaluation.rican Society of Gene and Cell Therapy.
www.moleculartherapy.orgThis study aimed to characterize disease progression in Borderdale
sheep with naturally occurring CLN5 and to monitor the efficacy of
CLN5 gene therapy longitudinally through a suite of in vivo tests.
Affected sheep share the main neuropathological features of the hu-
man disease, including progressive brain atrophy and loss of vision
from 11–12 months of age, and typically decline to a humane
endpoint before 22 months.14,15 The in vivo data presented here
show that both single-stranded adeno-associated viral serotype 9
(ssAAV9) and lentivirus-mediated (LV) ovine CLN5 gene transfer
to pre-clinically affected CLN5 lambs prevented stereotypical disease
development for an extended period, the only clinical sign observed
being delayed-onset visual loss. Furthermore, delivery of self-comple-
mentary (sc) AAV9-CLN5 to affected sheep at an early stage of
clinical disease (7 months) attenuated disease progression and brain
atrophy to beyond the lifetime of untreated affected sheep. Wide-
spread transduction of the brain and spinal cord was observed in
all treated sheep, regardless of the vector platform, post mortem.
These data provide a strong rationale for clinical translation to
CLN5-affected human patients.
RESULTS
Tolerance of CLN5 Gene Transfer by Pre-clinically Affected
Sheep
Six CLN5/ affected sheep received both intracerebroventricular
(i.c.v.) and intraparenchymal (IP) injections of ssAAV9 (n = 3) or
LV (n = 3) vectors expressing ovine CLN5 at 2–3 months of age,
before the onset of clinical disease (Table 1). Their rectal tempera-
tures, pulse, and respiratory rates remained normal throughout the
3-week post-injection observation period, and no behavioral changes
or clinical signs of an immune response were observed in these sheep,
monitored daily for 2 years after these single neurosurgical proced-
ures. All six treated sheep remained free of disease signs when aged
26–27 months, except for a much delayed onset of visual deficits,
and well exceeded the 22-month maximal life expectancy of un-
treated CLN5/ sheep. Five were euthanized for neuropathological
assessment at this age, and one ssAAV9-treated sheep remains alive
in the field, albeit blind, at 57 months of age.
Clinical Efficacy ofCLN5GeneTransfer to Pre-clinically Affected
Sheep
The long-term clinical benefit was assessed monthly against CLN5
heterozygous (CLN5+/) and untreated CLN5/ sheep using an
ovine-specific Batten disease rating scale (oBDRS; Table S1), similar
to those used for human NCLs.16,17 As expected for a recessive dis-
ease, CLN5+/ carriers were clinically normal throughout the study,
consistently scoring 40 (Figure 1A). Sheep treated before the develop-
ment of any disease signs also showed no functional deficits, being
clinically indistinguishable from healthy CLN5+/ controls for the
first 18 months, whereas the oBDRS scores of the untreated
CLN5/ sheep decreased to under 20, reflecting the natural progres-
sive disease course.
This successful trial was extended to determine any longer-term
consequences following treatment. A much-delayed loss of vision,apparent by 27 months, was the only disease manifestation noted.
Funduscopic examination revealed intermediary indicators of retinal
damage, mild tapetal hyperreflectivity, and blood vessel attenuation at
this time. Concomitant menace response deficits account for the de-
viation from normal observed on the oBDRS from 19 months (LV)
and 21months (ssAAV9), respectively (Figures 1A and 1B). Much de-
layed functional blindness (absent menace response) ensued (un-
treated CLN5/ sheep, 12.6 ± 0.4 months; LV-treated sheep,
20.7 ± 0.7 months; ssAAV9-treated sheep, 24.8 ± 1.3 months;
p < 0.0001) (Figure 1B). At 27 months, pupillary light reflexes were
sluggish in the treated sheep, and electroretinography (ERG) re-
sponses from the ssAAV9-treated sheep were severely diminished,
similar to those seen in untreated CLN5/ sheep at 15–17 months,
and abolished in the LV-treated sheep (Figure S1A).
The treated sheep were otherwise phenotypically normal at
27 months. They were alert and highly interactive with their environ-
ment and had developed strong social attachments within their
cohort and with animal care personnel, interacting through vocaliza-
tion and physical contact and detecting the presence of foreign sheep
or humans immediately. When grazing in the open field, they showed
no evidence of the stereotypical behavior, reduced mentation,
wide stance, manifest ataxia, and hindlimb paresis or localized seizure
activity seen in the advanced stages of ovine CLN5 disease (Figures
1D–1G).
In stark contrast, stereotypical disease progression had already
commenced in the untreated CLN5/ cohort at 6 months (Figure 1).
Initial manifestations were apprehensive walking with low head car-
riage and balking when in shadows, passing through gateways, or
negotiating steps. Vision deteriorated, and by 13 months, untreated
animals were functionally blind, exhibiting bilateral absence in
menace response, loss of visual tracking, and decreased acoustic star-
tle that affected their ability to flock. Proprioceptive and motor defi-
cits progressed to a wide stance, hindlimb ataxia, stumbling, and
intermittent episodes of localized muscle tremors, particularly of
the ears, eyelids, lips, and limbs. Behavioral changes included self-
segregation, repetitive actions such as aimless circling, and feeding ab-
normalities, including dribbling and sham grazing. From 15 months,
they lost body condition and demonstrated low mentation, extended
periods of somnolence, and poor or no responses to a variety of stim-
uli, including loud noises, flashing lights, and approaching humans.
Extremely hyperreflective foci in the retina were obvious to the naked
eye, and fundoscopy showed thinned retinal vasculature, together
indicative of photoreceptor damage. The neurological phenotype
from 17 months was accompanied by tremors ranging from subtle
to whole-body inducible seizures, defining their humane endpoint.
One of the ssAAV9-CLN5-treated sheep is still alive in the field at
57 months. Her menace response was diminished at 26 and absent
at 27 months, ERG amplitudes were extinguished by 29 months,
and she developed a pronounced head tilt. She was otherwise clini-
cally normal until 38 months, and then she began to show increased
somnolence and sitting and episodes of reduced awareness andMolecular Therapy Vol. 26 No 10 October 2018 2367
Table 1. Treatment Groups and Current Clinical Status of Treated Sheep
Sheep Genotype Treatmenta
Treatment





(Months)e Clinical Description Seizures
Trial 1 controls
1,103 CLN5+/ untreated NA NA NA M 18.4 normal 
1,118 CLN5+/ untreated NA NA NA M 19 normal 
1,121 CLN5+/ untreated NA NA NA M 18.7 normal 
1,128 CLN5+/ untreated NA NA NA M 57.8 normal 

















1,106 CLN5/ LV-MND-CLN5 2.1 3.6  109 i.c.v./IP W 26.9 deceased, blind 
1,117 CLN5/ LV-MND-CLN5 2.2 3.6  109 i.c.v./IP W 27.0 deceased, blind 
1,126 CLN5/ LV-MND-CLN5 2.4 3.6  109 i.c.v./IP F 27.1 deceased, blind 
1,105 CLN5/ ssAAV9.MND.CLN5 3.5 3.1  1012 i.c.v./IP F 27.1 deceased, onset of
visual deficits

1,109 CLN5/ ssAAV9.MND.CLN5 3.4 3.1  1012 i.c.v./IP F 57.0 alive, blind 
1,120 CLN5/ ssAAV9.MND.CLN5 2.8 3.1  1012 i.c.v./IP F 26.4 deceased, blind 
Trial 2 controls
1,100 CLN5+/ untreated NA NA NA F 23.8 normal 
1,105 CLN5+/ untreated NA NA NA F 23.7 normal 
1,106 CLN5+/ untreated NA NA NA F 23.7 normal 













1,164 CLN5/ scAAV9.CBh.CLN5 7.5 4.0  1012 i.c.v. F 32.3 alive, blind 
1,165 CLN5/ scAAV9.CBh.CLN5 7.5 4.0  1012 i.c.v. F 22.3 deceased, blind /+
1,170 CLN5/ scAAV9.CBh.CLN5 7.3 4.0  1012 i.c.v. F 32.1 alive, blind 
1,172 CLN5/ scAAV9.CBh.CLN5 7.3 4.0  1012 i.c.v. F 22.5 deceased, visual deficits 
aLV, lentivirus vector; AAV9, adeno-associated viral vector serotype 9; ss, single-stranded; sc, self-complementary; MND, myeloproliferative sarcoma virus enhancer, negative control
region deleted, dl587rev primer-binding site substituted promoter; CBh, hybrid chicken b-actin promoter.
bTransducing units (TUs) for LV; viral genomes (vgs) for AAV9.
ci.c.v., intracerebroventricular; IP, intraparenchymal.
dM, male; F, female; W, wether (castrated male).
eUntreated sheep were euthanized at their clinical humane endpoint. Treated sheep (boxed) remain alive unless indicated.
Molecular Therapydepression. Mild stereotypical behavior, including aimless wandering,
followed from 42 months (Figures 1F and 1G). Her oBDRS clinical
rating score plateaued at 43 months and remains at 22 currently,
equivalent to that of untreated CLN5/ animals at 16 months (Fig-
ure 1). At a healthy 80 kg, she has not shown the condition loss typical
of untreated CLN5/ sheep, still exhibits social and exploratory
behavior, recognizes familiar human voices, and takes advantage of
her weight and sense of smell to push much younger flockmates aside
to receive pelleted food rewards. She moves well within the control
flock without hitting obstacles, but her lack of vision becomes obvious2368 Molecular Therapy Vol. 26 No 10 October 2018when she is isolated and she can run directly into fences when
stressed.
Functional Efficacy of CLN5 Gene Transfer to Pre-clinically
Affected Sheep
Cognitive decline was assessed in a closed field maze test that relied
on the natural flocking instinct of sheep to motivate passage to con-
specifics penned in a goal area18,19 (Figures 2A and 2B). A food
incentive was added to encourage traversal because sheep can
become habituated to human contact and lose their natural
Figure 1. CLN5 Gene Therapy Provides Long-Term Clinical Efficacy to
CLN5-Affected Sheep
(A) CLN5/ sheep that received pre-clinical LV or ssAAV9-CLN5 gene therapy
(2–3 months) or scAAV9-CLN5 at an early clinical age (7 months) were assessed
on the multimodal ovine Batten disease rating scale (oBDRS; Table S1) and
compared against healthy CLN5+/ and untreated CLN5/ controls over
time. Lower scores reflect greater impairment. (B–G) The onset of phenotypic
disease traits were assessed, including (B) absent menace response, (C) maze
test failure, (D) ataxia, (E) tremors, (F) reduced mentation, and (G) stereotypical
behavior in the LV-, ssAAV9-, and scAAV9-treated cohorts and untreated
CLN5/ sheep. Each point represents the age of onset for an individual
sheep. Missing points indicate that the sheep did not yet exhibit the trait during
the study. The dashed portion of the line for the scAAV9-treated sheep arises
www.moleculartherapy.orgwariness. No difference in maze performance was discernible be-
tween treated sheep and healthy CLN5+/ sheep for many months
after untreated CLN5/ sheep reached end-stage disease (Fig-
ure 2A). Treated sheep walked or ran through the maze with their
heads held high, avoiding the obstacles and error zones, at traverse
times usually faster than the heterozygote controls. The effects of
their treatment-delayed visual loss surfaced from 24 and 25 months
for the LV and AAV9 cohorts, respectively (Figure 1). Traverse
times and failure rates increased (Figures 2A and 1C), and they
began to collide with maze obstacles.
Untreated CLN5/ sheep showed progressive navigational decline
(Figure 2A) and an affected phenotype from an early age. Despite
their deteriorating vision (Figure 1B), they were able to negotiate
the maze for another few months (Figure 1C), albeit at progressively
longer traverse times. By 16 months, they failed to transit the error
zone or became too akinesic to complete the maze, and testing was
abandoned. They still tended to avoid obstacles, pulling up short,
but failed to find a way around.Maintenance of Brain Volume and Structure after CLN5 Gene
Transfer to Pre-clinically Affected Sheep
Three-dimensional reconstructions from longitudinal compu-
ted tomography (CT) scanning were used to monitor brain
atrophy in vivo20 and revealed a corrective effect of pre-clinical
CLN5 gene therapy (Figure 3). Treated brains maintained the
structural appearance of healthy control brains, with no evidence
of the atrophy characteristic of untreated CLN5/ brains,
particularly the notable degeneration of the occipital and parietal
cortices that generalizes to the entire cortical mantle by
19 months.
Treatment with either ssAAV9 or LV vector largely attenuated vol-
ume loss, but differences in initial volumes and subsequent rates of
change varied between individuals, somewhat obscuring the data
(Figure 4A). Differences becamemuch clearer whenmean cumulative
intracranial volume differences in each group were plotted (Fig-
ure 4B). The cranial volumes of the ssAAV9-treated sheep closely fol-
lowed those of theCLN5+/ control animals, and volumetric increases
for the LV-treated sheep were even greater. This contrasted with the
shrinkage of the untreated CLN5/ brains.
The veracity of the structures derived from CT scanning was
confirmed by MRI of treated sheep at 25 months. Overall brain struc-
ture and architecture remained normal (Figure 5). Ventricles of
treated animals were not noticeably enlarged, nor were overt
widening of the subarachnoid cerebrospinal fluid (CSF) spaces or sul-
cal prominence observed. There was none of the cranial ossification
present in younger untreated CLN5/ controls.from data from the two animals still alive. All data are expressed as means ±
SEM. *p < 0.05, **p < 0.01, nonparametric Mann-Whitney test where
appropriate.
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Figure 2. CLN5 Gene Therapy Delays the Onset of Cognitive Deficits in
CLN5-Affected Sheep
Vision and cognition were assessed in closed field mazes. (A) Mean traverse times
for sheep treated pre-clinically with LV or ssAAV9-CLN5 compared with healthy
Molecular Therapy
2370 Molecular Therapy Vol. 26 No 10 October 2018Longitudinal CT of the remaining ssAAV9-treated sheep revealed
that, after plateauing at 102.4 ± 0.7 mL from 11–27 months, her intra-
cranial volume began to decline. It was 84.2 mL at 51 months, similar
to that of a 16-month-old untreated CLN5/ animal, but the only
observable phenotypic traits are mild.
Disease Progression Halted after CLN5 Gene Transfer to
Clinically Affected Sheep
A second trial tested the efficacy of CLN5 gene therapy in sheep with
established disease (Table 1). Four 7-month-old CLN5/ sheep, with
evident brain atrophy and early clinical signs, received i.c.v. injections
of an scAAV9 vector expressing ovine CLN5. The treatment was well
tolerated, and aside from visual loss, there was a paucity of evidence of
further disease progression. Two of the four sheep were euthanized at
23 months for neuropathological analyses, whereas the other two
remain alive and well at 32 months
Clinical efficacy was monitored monthly on the oBDRS (Figure 1A).
These sheep already had a mild clinical phenotype at enrollment,
including a slight head tilt and/or low head carriage and wariness
of shadows, and they crouched when traveling through a confined
gateway. Unlike the sheep treated earlier, vision loss was not delayed.
These sheep lacked menace responses by 12–14 months, as do un-
treated CLN5/ sheep (Figure 1B). ERG amplitudes were extin-
guished in one sheep by 14 months, another two retained a response
until 20 months, whereas the fourth had positive photopic and
scotopic responses to 22 months (Figure S1B). Strikingly, there has
been no dramatic advance in motor, neurological, or behavioral
dysfunction in this scAAV9-treated cohort from 12 to 32 months.
One sheep had short periods of heightened somnolence and exhibited
inducible facial tics and mild circling behavior on stress prior to
euthanasia at 23 months, but the collective oBDRS scores of the
two remaining treated sheep have plateaued just below 30 (Figure 1).
To compare, age-matched untreated CLN5/ flockmates developed
stereotypical CLN5 disease with manifest seizures and negative ERGs
from 16–21 months, prompting euthanasia at 18–23 months when
oBDRS scores ranged from 17.5–11.5 (Figure 1A).
Following relaxation by the New Zealand Environmental Protection
Agency regarding the status of AAV9-treated animals, sheep on
this second trial were maintained outdoors, enabling more complex
maze testing (Figure 2D). The maze traverse times of the untreated
CLN5/ sheep reflected their progressive slowing and ultimate fail-
ure, whereas the scAAV9-treated sheep retained speed and the ability
to traverse for longer, albeit to varying extents (Figures 2C and 1C).
The sheep with ERG amplitudes extinguished at 14 months struggled
to complete the maze thereafter, but the other three still completedCLN5+/ and untreatedCLN5/ controls (2 runs per animal at each time) in the first
maze configuration (B). (C) Mean traverse times for sheep treated with scAAV9-
CLN5 at an early clinical disease stage (5 runs per animal) compared with healthy
CLN5+/ and untreated CLN5/ controls in the second maze configuration (D). All
data are the means ± SEM. The earliest times at which traverse times differed be-
tween cohorts are indicated. *p < 0.05, Student’s t test.
Figure 3. Three-Dimensional Modeling of Gross Neuroanatomy after Pre-Clinical CLN5 Gene Therapy
Representative three-dimensional models of the sheep cranium and lateral ventricles reconstructed from CT images showing no discernible differences in the gross anatomy
of the pre-clinically treated brains and a healthyCLN5+/ control at 27months. Both lacked the pronounced atrophy visible in the younger untreatedCLN5/ cerebral cortex
at 19 months. Note the relative sparing of the affected cerebellum. The scale bar represents 2 cm.
www.moleculartherapy.orgmost or all of the five maze runs within the allocated 120 s at
19 months. The two sheep still alive were removed from the monthly
testing regime at 24–25 months when they could no longer traverse
the maze.
Sheep in this more complex maze wore harness-attached global posi-
tioning system (GPS) units to track their movements (Figure 6).
Healthy CLN5+/ control sheep followed a uniform track through
the maze with few pauses, avoided obstacles, and reached conspecifics
in the goal area quickly. Initially, treated sheep also followed the most
direct route. With time they found it harder to enter or exit the maze
but still completed most of their runs until 24 months. In contrast,
untreated CLN5/ sheep took longer and used a more random
path from as early as 8 months. As their disease progressed, they
lost any social and/or exploratory behavior and just stood in the
maze arena bleating. By 19 months, they circled compulsively in
the start area (Figure 6) or were too affected to participate in the
testing (Figure 1C).
Longitudinal CT scanning has indicated little post-injection brain at-
rophy in the scAAV9-treated sheep to date. Intracranial volumeslargely plateaued from 89.5 ± 1.2 mL pre-injection to 87.8 ± 0.8 mL
at 22 months (all four animals), falling slightly to 85.6 ± 1.7 mL at
32 months (the two remaining animals) (Figures 4A and 4C). Treated
brains actually increased in size over the first 3 months post-injection
before two periods of mild atrophy and plateaux; hence, cumulative
intracranial volume changes have been minimal (2.5 ± 0.8 mL
from injection to 31 months) in contrast to the rapid atrophy seen
in untreated CLN5/ sheep, which causes a loss of 6.7 ± 1.3 mL of
intracranial volume from 7 to 19 months. Two scAAV9-treated ani-
mals were sacrificed at 23 months to determine the extent of CLN5
expression in the CNS. Immunohistochemistry revealed strong trans-
duction throughout the brain, particularly in the hippocampus
and cortical gray matter (Figure 7) as well as in the cerebellum and
spinal cord.
DISCUSSION
These trials are the first to demonstrate the efficacy of virus-mediated
CLN5 gene therapy in a large animal model of NCL using outcome
measures adapted from human medicine. First, pre-clinically affected
sheep were treated with combinatorial IP and i.c.v. injections of either
ssAAV used in gene transfer studies into the brain parenchyma inMolecular Therapy Vol. 26 No 10 October 2018 2371
Figure 4. In Vivo Neuroimaging Revealed Normalization or Stabilization of
Intracranial Volumes after CLN5 Gene Therapy
Longitudinal CT scans of treated sheep brains compared against control data. (A)
Actual scan volumes of sheep brains. (B) Data presented as cumulative volume
changes over time post-injection show normalization of intracranial volumes after
pre-clinical CLN5 gene therapy. (C) Data presented as cumulative volume changes
over time post-injection show extended volumetric retention in sheep treated at an
early clinical stage (7 months) compared with the ongoing atrophy of the untreated
affected brains. All data are expressed as means ± SEM.
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2372 Molecular Therapy Vol. 26 No 10 October 2018CLN2 rodent and non-human models2,3,21,22 or lentiviral vectors that
successfully mediated transduction of sheep brains in vivo.23 The
ambition was to preferentially treat the CNS using an ubiquitous
myeloproliferative sarcoma virus enhancer, negative control region
deleted, dl587rev primer-binding site substituted (MND) promoter
previously tested in our sheep23 and doses derived from human,
sheep, non-human primate, and rodent studies.22–24 The original pro-
tocol envisaged sacrifice of these animals at 18 months for post mor-
tem neuropathological analyses to judge the efficacy of treatment.
However, they remained clinically indistinguishable from unaffected
controls on the oBDRS at this age (Figure 1), so they were kept alive,
and monitoring was continued. Longitudinal neuroimaging and
three-dimensional modeling showed that their brain structure, archi-
tecture, and size were normalized (Figures 3 and 4). Their quality of
life was profoundly improved; they well exceeded the typical lifespan
of untreated animals, and there were no signs of disease except late-
onset visual deficits that would not have been detected had the trial
been terminated at 18 months.
The three LV-treated sheep were euthanized at 27 months following
indoor housing restrictions imposed by New Zealand law. AAV9-
treated animals were exempted from this restriction at the same
time; however, the decision was made to euthanize two of the three
ssAAV9-treated sheep at 27 months to allow a comparative post mor-
tem assessment of CLN5 expression between the two vectors and to
look for pathological correction or any chronic immune response
over time. These neuropathological studies are underway. The re-
maining ssAAV9-treated sheep is still alive and well at 57 months
of age, nearly triple the maximal life expectancy of a CLN5/ animal.
Although blind, she lives in the field and does not require the indoor
intensive nursing of end-stage CLN5/ animals. Monitoring for any
disease or age-related signs or long-term CNS or peripheral problems
continues.
Given that most human cases of NCL only become apparent
upon diagnosis following the development of disease symptoms,
7-month-old CLN5/ sheep with established clinical disease were
treated in a second trial. Here the vector platform of choice changed
from single-stranded to scAAV vectors following their purported 10-
to 100-fold greater transduction efficiency, which potentially reduces
the doses required, increases efficacy, and decreases the time between
transduction and functional expression.25–28 The hybrid chicken
b-actin promoter (CBh) promoter was chosen for its ability to provide
the strong, long-term, and ubiquitous CNS expression shown in other
animal studies.29 The multiple IP injections of the first trial were
Figure 5. MRI Confirmed Preservation of Neuroanatomical Structure after Pre-clinical CLN5 Gene Therapy
Volumetric T1-weightedmagnetic resonance images in the horizontal (top) and coronal (bottom) views of a 19-month-old healthyCLN5+/ control and an untreatedCLN5/
sheep brain compared with brains frommuch older (27 months) sheep that received LV or AAV9-CLN5 gene therapy before the development of clinical signs. Treatment with
either vector preserved neuroanatomical structure, protecting against the profound cortical atrophy (top arrow), prominent ventricular enlargement (center arrow), and cranial
thickening (bottom arrow) seen in the untreated CLN5/ brain. The scale bars represent 1 cm. CB, cerebellum; CN, caudate nucleus; HC, hippocampus; LV, lateral
ventricle; OC, occipital cortex; Th, thalamus.
www.moleculartherapy.orgabandoned, and sheep in the second trial received i.c.v.-only bilateral
injections consequent to the success of this delivery route in other
large animal studies.30,31
The scAAV9 injections suspended disease progression in these sheep,
and two treated sheep remain alive at 32 months. That they went blind
at a similar rate as untreated CLN5/ sheep was not unexpected
because baseline intracranial volume measurements indicated consid-
erable pre-injection atrophy of the occipital lobe, which continues in
untreated CLN5/ sheep (Figure 5).32 Treatment halted this atrophy,
and little further occurred over the following 23 months (Figure 4).
Simple maze tests based on those used in sheep for a number of appli-
cations,33–37 including spatial learning andmemory studies,13 became
a valuable adjunct to the clinical studies. Pre-clinically treated sheep
retained their ability to navigate themaze well beyond the age at which
untreated CLN5/ sheep could not, at traverse times even faster than
the unaffected cohort, possibly because they were more habituated to
the food reward than the pasture-raised controls. Although they even-
tually went blind, differences upon clinical examination and end-stage
maze behavior (e.g., hitting obstacles) suggest a difference in the path-
ophysiological cascade initiating visual disturbances from that in un-
treated CLN5/ animals. Although loss of vision in the untreated
CLN5/ sheep paralleled atrophy of the visual cortex noted in histo-
logical, MRI,32 and CT studies (Figures 3, 4, and 5), no such atrophy
was observed in the pre-clinically treated brains, even at 27 months.
It is likely that the gene therapy prevented the cortical neurodegener-
ative-driven blindness seen first in untreated CLN5/ sheep but that
the vector and/or recombinant CLN5 protein did not penetrate to, or
persist in, the retina to prevent its long-term degeneration. Thus, the
contemporaneous problems experienced by the treated sheep in navi-gating themaze were likely to be associated with the later-onset retinal
atrophy. This hypothesis is being explored in ongoing neuropatholog-
ical examinations of the treated sheep brains, whichwill also reveal any
differences in efficacy and CLN5 biodistribution between the various
promoters and doses used.
Similar findings were reported in dogs with CLN2 NCL after i.c.v.
AAV2-mediated delivery of the soluble lysosomal enzyme tripeptidyl
peptidase 1 (TPP1)30. Like the sheep, these dogs had an extended
lifespan after treatment, with protection from cognitive decline and
delayed disease onset and progression and a similar dichotomy of
leading symptoms. Treatment did not delay the retinal degeneration
in these dogs either.
The performance of certain animal species in cognitive or behavioral
tasks, including maze tests, depends on visual ability.38,39 Here, GPS
technology showed that, although post-symptomatically treated
sheep went blind and moved slowly, they could still navigate the
maze at 22 months of age (Figure 6), suggesting intact spatial memory
skills learned when still sighted. Untreated animals lose cognition
and, thus, navigational ability well before this age. This technology
will be important when testing the efficacy of future combined
brain-directed and ocular gene therapies.
Sheep are ideal animals in which to assess the safety, efficacy, and
long-term prognosis of gene therapy. They have a large gyrencephalic
brain and similar live body weights, spine dimensions, CSF volumes,
and pulmonary and cardiac parameters as humans.40 Presently, sheep
models of inherited disease are restricted to flocks arising from cases
diagnosed on referral. Completion of the full genome sequence of
sheep41 and the advent of next-generation sequencing technologiesMolecular Therapy Vol. 26 No 10 October 2018 2373
Figure 6. GPS Tracking of Traversal of a Closed Field Maze Highlighted the
Delay in Cognitive Decline after CLN5 Gene Therapy of Clinically Affected
Sheep
GPS positional data were collected at 1-s intervals (dots), and five traverses through
the close field maze (Figure 2D) were plotted for a representative healthy CLN5+/
control, an untreated CLN5/ sheep, and an scAAV9-CLN5-treated sheep at
different ages. The direct trajectory of the CLN5+/ sheep persisted throughout the
testing, whereas untreated CLN5/ sheep showed a less uniform path as early as
8 months, with compulsive circling and ultimate failure by 19 months.
Molecular Therapymake it feasible to screen populations of sheep for genetic variants to
yield animal model candidates for an array of diseases.42 Recent ad-
vances in gene modification technologies, such as CRISPR/Cas9
genome editing, are being applied to sheep to generate purpose-built
model flocks, increasing the use of this species for model studies. The
in vivo tests described here will provide robust, quantitative natural
history and translational data for these novel sheep models.2374 Molecular Therapy Vol. 26 No 10 October 2018Treated sheep may eventually develop disease because of vector attenu-
ation or the protein becoming non-functional with time. These consid-
erationswill determine the timing of the eventual postmortemneuropa-
thology studies on the treated sheep still alive and give insight into
whether medium-term successful treatments could benefit from subse-
quent re-injections of vector using serotypes chosen to prevent immune
rejection. Although intervention at the earliest possible stage will opti-
mize patient outcome, CLN5 gene therapy to clinically affected animals
still had a telling effect, slowing brain atrophy and delaying clinical pro-
gression, indicating that clinically affected patients may also benefit.
Our studies so far indicate that ssAAV9, scAAV9, and LV vectors all
resulted in effective transduction and amelioration of disease-related
pathology. All of the viral cassettes contained the wild-type sheep
CLN5 cDNA sequence with translation from the ovine ATG initiation
site in exon 1, which aligns with the third ATG in the human sequence,
to yield a 361-amino acid peptide,15 in line with results of human lyso-
some proteomic studies.43 Unfortunately, a number of workers have
assumed that the first ATG in the humanCLN5 gene is the start codon,
leading to deductions from function and localization studies of uncer-
tain veracity.44,45 This must be borne in mind when designing vectors
expressing the CLN5 protein for human treatments.
In conclusion, these studies establish the efficacy of viral-mediated
gene transfer in an ovine CLN5 NCL and provide a particularly press-
ing case for translation to patients, including those with clinically




Borderdale sheep were diagnosed at birth15 and maintained at Lincoln
University under NIH guidelines for the care and use of animals in
research and theNZAnimalWelfare Act (1999). All experimental pro-
tocols were approved by the Lincoln University Animal Ethics and
Institutional Biosafety Committees. Table 1 summarizes the study
design. Six CLN5/ pre-clinically affected lambs received bilateral
i.c.v. and IP injections of lentiviral (n = 3) or ssAAV9 vectors (n = 3)
encoding ovine CLN5 at 2–3 months and were housed in an indoor
PhysicalContainment 2 sheep facility for 2 yearswith dailymonitoring,
in compliance with New Zealand (NZ) Environmental Protection Au-
thority (EPA) requirements. In a second trial, four lambs with clinical
signs of disease received bilateral i.c.v. injections of scAAV9-CLN5 at
7 months and were maintained under normal outdoor pastural condi-
tions following a change in EPA requirements, as were all age-matched
CLN5+/ unaffected and untreated affected CLN5/ control sheep.
Vectors
LV and recombinant single-strandedAAV9 constructs, encoding ovine
CLN5 (GenBank: NM_001082595) under the control of the myeloid
proliferativeU3 enhancer element (MND),were produced by theOtago
Viral Vector Facility (EPA approval GMDO3091 andGMD101648) for
testing in CLN5/ sheep prior to the onset of clinical disease. LVs,
pseudotyped with the vesicular stomatitis virus glycoprotein, were
Figure 7. Long-Term Expression of the CLN5 Protein
after CLN5 Gene Therapy
Representative micrographs of the hippocampal and
cortical regions in sagittal sheep brain sections of a
CLN5+/ control, an untreated CLN5/ sheep, and a
CLN5/ sheep that received scAAV9-CLN5 treatment at
7 months, immunostained using an anti-rabbit CLN5 anti-
body. Endogenous CLN5 protein expression was evident
throughout the control brain, which was lacking in the un-
treated CLN5/ sheep brain. In contrast, strong CLN5
immunoreactivity was noted in the treated sheep brain over
15 months after intraventricular delivery of scAAV9-CLN5.
Similar results were seen after pre-clinical delivery of LV or
ssAAV9 vectors. CLN5-expressing cells in the treated
hippocampal and cortical pyramidal cell layers were
morphologically neuron-like. The scale bar represents
500 mm.
www.moleculartherapy.orgpackaged using a second-generation packaging system and titrated as
described previously.23 Functional titers were determined by serial dilu-
tion on 293T cells, with confirmation by in vitro immunofluorescence
72 hr post-transduction. Recombinant ssAAV9-CLN5 was generated
by standard triple transfectionmethods into 293T cells using packaging
and transgene plasmids obtained from the University of Pennsylvania
(PA, USA). Recombinant scAAV9, expressing codon-optimized ovine
CLN5 under the control of the CBh promoter (scAAV-CLN5), was pro-
duced by theUniversity ofNorthCarolinaGeneTherapyCenterVector
Core (NC, USA) by triple transfection of HEK293 cells, iodixanol
gradient centrifugation, and ion exchange chromatography as described
previously.46 Vectors were formulated in 350 mM PBS containing 5%
sorbitol, and titers were determined by qPCR.46
Vector Delivery
Stereotactic surgical procedures were used as described previously.23
Pre-clinical CLN5/ affected sheep received bilateral injections at
2–3 months into the lateral cerebral ventricles and the occipital and
parietal cortices via four burr holes. Each lamb received a total dose
of either 3.6  109 transducing units (TUs) of LV-CLN5 (110 mL
per ventricle; 26 mL per parenchymal site; vector titer, 1.1  1010MolecuTUs ml1) or 3.1  1012 viral genomes (vgs) of
ssAAV9-CLN5 (500 mL per ventricle; 25 mL per
parenchymal site; vector titer, 2.85  1012
vgs ml1) (Table 1). The four clinically affected
CLN5/ sheep each received bilateral i.c.v. in-
jections of 4.0  1012 vgs of scAAV9-CLN5
(287 mL vector diluted in PBS to a final
volume of 400 mL per ventricle; vector titer,
7.0  1012 vg ml1).
Neurological Examination
Physical and neurological clinical assessments
were performed monthly on the treated sheep
and cohorts of healthy CLN5+/ controls and un-
treated CLN5/ sheep. An oBDRS (Table S1)was developed, similar to those used for human NCLs.16,17 Body con-
dition scores and weights were recorded. Mentation, gait, head car-
riage, and postural traits as well as manifest tremors or seizure onsets
were reported in conjunction with cranial nerve function tests. Each
parameter was scored from 4 to 0 (normal to abnormal) by two
blinded investigators based on the degree of deviation from healthy
function; scores were averaged when there was a discrepancy and
then combined to give a total out of 40.
ERG
A single ERG session was performed on the pre-clinically treated
sheep when they were 27 months old. scAAV9-treated sheep in the
second trial were tested every second month against untreated
CLN5+/ and CLN5/ controls. Mixed receptor response ERG re-
cordings were obtained from each eye after 5 min of dark adaptation
using a veterinary ERG system (Eickemeyer, Tuttlingen, Germany).
Maze Testing
Sheep cognition was assessed monthly via performance in a closed
field maze (Figure 2B) under daytime photopic light, and the times
required to traverse the maze were recorded. Sheep negotiated thelar Therapy Vol. 26 No 10 October 2018 2375
Molecular Therapymaze twice on each testing day. Testing in the second, more complex
maze (Figure 2D) was expanded to five runs per day, and sheep were
fitted with harness-attached GPS loggers to collect their position in
the maze arena every second. Monthly testing continued until the
sheep were unable to complete the maze.
Quantitative Analysis of Brain Atrophy
Brain CT imaging of sheep anesthetized by intravenous injection of
0.8 mg/kg live-weight diazepam (Pamlin injection, Troy Laboratories
NZ, Auckland, NZ) and 17mg/kg live-weight of ketamine hydrochlo-
ride (Phoenix ketamine injection, Phoenix Pharm Distributors,
Auckland, NZ) was carried out bimonthly. Coronal slices were ac-
quired at 1-mm intervals, 120 kV, 100 mA, 2 s rotation time on a
GE Prospeed CT scanner (GE Healthcare, Hyugo, Japan). Three-
dimensional modeling and intracranial volumetrics were performed
using the three-dimensional slicer 4.3.1 freeware (https://www.
slicer.org/).47 That intracranial volumes are good surrogates for brain
volumes was confirmed by comparing the scanned volumes of healthy
control (n = 14) and NCL-affected sheep (n = 11) post mortem with
the volumes of the removed brains, measured by water displacement
(K.N.R., N.L.M., N.G. Anderson, C.R. Bunt, M.P.W., T.R.M., G.K.B.,
D.N.P., unpublished data).
A single structural T1-weighted magnetic resonance image of each
sheep brain was acquired on a 3-Tesla GE HDxt MRI scanner (GE
Healthcare, Waukesha, WI, USA) with an eight-channel head coil
(spoiled gradient recalled echo brain volume imaging (BRAVO)
acquisition, echo time/repetition time/interval time (TE/TR/TI) =
5.18/12.44/400 ms, flip angle = 15, field of view (FOV) = 200 mm,
acquisition matrix = 256  256, slice thickness = 0.8 mm, voxel
size = 0.78  0.78  0.8 mm3, scan time = 6:24).
Immunohistochemistry
Methods were similar to those described previously.23 Brains were
perfusion-fixed via the carotid artery with 10% formalin in
0.9% NaCl post mortem. After equilibration in 20% sucrose and
10% ethylene glycol in 0.9% NaCl for 7 days, brain hemispheres
were frozen at 80C. Sequential 50-mm sagittal sections were
cut on a sliding microtome (Microm International, Walldorf, Ger-
many) and stored at 20C in 96-well plates in cryoprotectant
(PBS) containing 30% ethylene glycol, 15% sucrose, and 0.05% so-
dium azide).
Antibodies were diluted in 10% normal goat serum (NGS) in PBS
(pH 7.4) containing 0.3% Triton X-100 (Sigma-Aldrich) (PBST).
Test sections were thawed and blocked with 1% H2O2 in PBST for
30 min and then for 1 hr in 15% NGS prior to overnight incubation
in rabbit polyclonal anti-CLN5 (Dr. Stephanie Hughes, University of
Otago; 1:500). Immunoreactivity was detected using biotinylated
goat anti-rabbit immunoglobulin G (IgG) (Sigma-Aldrich, B7389;
1:1,000) for 4 hr, followed by ExtrAvidin peroxidase (Sigma-
Aldrich, E2886; 1:1,000) for 4 hr. Staining was visualized using
0.5 mg/mL 3,30-diaminobenzidine (DAB; Sigma-Aldrich, D5637)
and 0.01% H2O2 in PBS.2376 Molecular Therapy Vol. 26 No 10 October 2018Statistics
One-way ANOVAwas used to assess the statistical significance of dif-
ferences between the control and treatment groups (GraphPad
Prism 7, GraphPad, La Jolla, California, USA). Pairwise comparisons
were then performed between treatment groups using the Mann-
Whitney test or Student’s t test as indicated. Data are expressed as
means ± SEM, and p % 0.05 was considered significant.SUPPLEMENTAL INFORMATION
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